{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:42:01Z","timestamp":1785865321493,"version":"3.56.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases Now"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.idnow.2025.105243","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:26:02Z","timestamp":1767745562000},"page":"105243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antimicrobial susceptibility testing of anaerobes \u2212 Challenges and potential solutions for identifying breakpoints using the disk-diffusion method, based on re-analysis of a large panel of anaerobes"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6814-8739","authenticated-orcid":false,"given":"Luc","family":"Dubreuil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idnow.2025.105243_b0005","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1469-0691.2010.03256.x","article-title":"on behalf of the ESCMID study group on antimicrobial resistance in anaerobic bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience","volume":"17","author":"Nagy","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idnow.2025.105243_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.anaerobe.2019.102111","article-title":"Antimicrobial susceptibility profiles of anaerobic bacteria, isolated from human clinical specimens, within different European and surrounding countries a joint ESGAI study","volume":"61","author":"Veloo","year":"2020","journal-title":"Anaerobe"},{"key":"10.1016\/j.idnow.2025.105243_b0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.anaerobe.2014.05.004","article-title":"Recent evolution of antibiotic resistance in the anaerobes as compared to previous decades","volume":"31","author":"Boyanova","year":"2015","journal-title":"Anaerobe"},{"key":"10.1016\/j.idnow.2025.105243_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.anaerobe.2021.102463","article-title":"on behalf of the ESCMID Study Group for Anaerobic Infections (ESGAI). Correlation between antibiotic resistance and clinical outcome of anaerobic infections; mini-review","volume":"72","author":"Dubreuil","year":"2021","journal-title":"Anaerobe"},{"key":"10.1016\/j.idnow.2025.105243_b0025","unstructured":"CLSI Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria. 9th ed. CLSI standard M11. Wayne, PA: Clinical and Laboratory Standards Institute; 2018. Available from: https:\/\/clsi.org\/shop\/standards\/m11\/."},{"key":"10.1016\/j.idnow.2025.105243_b0030","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST) [Internet]. 2025. Breakpoint tables for interpretation of MICs and zone diameters. Version 15.0 [cited January 1, 2025]. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_15.0_Breakpoint_Tables.pdf."},{"key":"10.1016\/j.idnow.2025.105243_b0035","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.pathol.2017.10.020","article-title":"Gram negative anaerobe susceptibility testing in clinical isolates using Sensititre and E test methods","volume":"50","author":"Hughes","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.idnow.2025.105243_b0040","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1128\/jcm.29.10.2197-2203.1991","article-title":"Evaluation of the E test for susceptibility testing of anaerobic bacteria","volume":"29","author":"Citron","year":"1991","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.idnow.2025.105243_b0045","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1128\/JCM.05397-11","article-title":"First comprehensive evaluation of the MIC evaluator device compared to E test and CLSI reference dilution methods for antimicrobial susceptibility testing of clinical strains of anaerobes and other fastidious bacterial species","volume":"50","author":"Rennie","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.idnow.2025.105243_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.anaerobe.2021.102358","article-title":"False amoxicillin\/clavulanic acid susceptibility in Bacteroides fragilis using gradient strip tests","volume":"69","author":"Rentenaar","year":"2021","journal-title":"Anaerobe"},{"key":"10.1016\/j.idnow.2025.105243_b0055","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s10096-018-3369-5","article-title":"A comparison of sensititre TM Anaerobe MIC plate with ATB ANA\u00ae test for the routine susceptibility testing of common anaerobe pathogens","volume":"37","author":"Cherkaoui","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.idnow.2025.105243_b0060","unstructured":"Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie [Internet]. 2024. CA-SFM 2024. Comit\u00e9 de l\u2019antibiogramme de la Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie - Recommandations 2024 V.1.0 Juin [cited June 1, 2024]. Available from: https:\/\/www.sfm-microbiologie.org\/wp-content\/uploads\/2024\/06\/CASFM2024_V1.0.pdf."},{"issue":"6","key":"10.1016\/j.idnow.2025.105243_b0065","article-title":"Diagnostic and epidemiological landscape of anaerobic bacteria in Europe, 2020\u20132023 (ANAEuROBE)","volume":"65","author":"Boattin","year":"2025","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idnow.2025.105243_b0070","doi-asserted-by":"crossref","unstructured":"Dubreuil L, on behalf the Members of the CA-SFM 2019. Improvement of a disk diffusion method for antibiotic susceptibility testing of anaerobic bacteria. French recommendations revisited for 2020. Anaerobe 2020;64:102213. 10.1016\/j.anaerobe.2020.102213.","DOI":"10.1016\/j.anaerobe.2020.102213"},{"key":"10.1016\/j.idnow.2025.105243_b0075","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1128\/jb.176.14.4376-4384.1994","article-title":"Insertional activation of cepA leads to high-level beta-lactamase expression in Bacteroides fragilis clinical isolates","volume":"176","author":"Rogers","year":"1994","journal-title":"J Bacteriol"},{"key":"10.1016\/j.idnow.2025.105243_b0080","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ijantimicag.2006.07.021","article-title":"on behalf of the ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Examination of cfiA-mediated carbapenem resistance in Bacteroides fragilis strains from a European antibiotic susceptibility survey","volume":"28","author":"S\u00f3ki","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idnow.2025.105243_b0085","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/jac\/33.5.1029","article-title":"Multicentre survey in France of the antimicrobial susceptibilities of 416 blood culture isolates of the Bacteroides fragilis group","volume":"33","author":"Patey","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2025.105243_b0090","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1128\/AAC.40.10.2266","article-title":"In vitro activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms","volume":"40","author":"Dubreuil","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idnow.2025.105243_b0095","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1128\/AAC.47.11.3667-3671.2003","article-title":"In vitro evaluation of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria","volume":"47","author":"Liebetrau","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idnow.2025.105243_b0100","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1075-9964(03)00066-0","article-title":"Antibiotic resistance among Anaerobic Gram-negative bacilli: lessons from a French Multicentric Survey","volume":"9","author":"Behra-Miellet","year":"2003","journal-title":"Anaerobe"},{"key":"10.1016\/j.idnow.2025.105243_b0105","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/jac\/dkh248","article-title":"Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents","volume":"53","author":"Koeth","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2025.105243_b0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijantimicag.2006.01.011","article-title":"In vitro activity evaluation of ertapenem and nine other comparators against anaerobic bacteria","volume":"28","author":"Behra-Miellet","year":"2006","journal-title":"Int J Antimicrob Agent"},{"key":"10.1016\/j.idnow.2025.105243_b0115","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ijantimicag.2007.11.006","article-title":"The ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria (ESGARAB). European surveillance study on antimicrobial susceptibility of Gram-positive anaerobic cocci","volume":"31","author":"Brazier","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idnow.2025.105243_b0120","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.medmal.2008.03.007","article-title":"Monitoring of antibiotic resistance of gram negative anaerobes","volume":"38","author":"Singer","year":"2008","journal-title":"Med Mal Inf"},{"key":"10.1016\/j.idnow.2025.105243_b0125","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.patbio.2010.03.006","article-title":"Activity of doripenem against anaerobic bacteria","volume":"59","author":"Dubreuil","year":"2011","journal-title":"Pathol Biol"},{"key":"10.1016\/j.idnow.2025.105243_b0130","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ijantimicag.2012.02.013","article-title":"Anti-Anaerobic activity of a new \u00df-lactamase inhibitor NXL104 in Combination with \u00df-lactams and Metronidazole","volume":"39","author":"Dubreuil","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idnow.2025.105243_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.anaerobe.2020.102220","article-title":"Molecular basis of macrolide-lincosamide-streptogramin (MLS) resistance in Finegoldia magna clinical isolates","volume":"64","author":"Gu\u00e9rin","year":"2020","journal-title":"Anaerobe"},{"key":"10.1016\/j.idnow.2025.105243_b0140","unstructured":"CLSI. M100 Performance Standards for Antimicrobial Susceptibility Testing. 36th ed. CLSI 2022, Clinical and Laboratory Standards Institute, Wayne, PA. Available from: https:\/\/clsi.org\/shop\/standards\/m100\/."},{"key":"10.1016\/j.idnow.2025.105243_b0145","unstructured":"U.S. Food and Drug Administration [Internet]. 2009. Guidance for industry and FDA - Class II special controls guidance document: antimicrobial susceptibility test (AST) systems [cited August 28, 2009]. Available from: https:\/\/www.fda.gov\/media\/88069\/download."},{"key":"10.1016\/j.idnow.2025.105243_b0150","unstructured":"EUCAST [Internet]. 2022. EUCAST disk diffusion methodology and tentative QC criteria for selected rapidly growing anaerobic bacteria on Fastidious Anaerobe Agar (FAA). Version 1.0 [cited January 2, 2023]. Available from: https:\/\/www.eucast.org\/ast_of_bacteria\/disk_diffusion_methodology."},{"key":"10.1016\/j.idnow.2025.105243_b0155","doi-asserted-by":"crossref","first-page":"1695e1","DOI":"10.1016\/j.cmi.2021.03.028","article-title":"Development of a EUCAST disk diffusion method for the susceptibility testing of rapidly growing anaerobic bacteria using Fastidious Anaerobe Agar (FAA): a development study using Bacteroides species","volume":"27","author":"Bavelaar","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idnow.2025.105243_b0160","doi-asserted-by":"crossref","unstructured":"Matuschek E, Copsey-Mawer S, Petersson S, \u00c5hman J, Morris TE, Kahlmeter G. The European committee on antimicrobial susceptibility testing disc diffusion susceptibility testing method for frequently isolated anaerobic bacteria. Clin Microbiol Infect 2023;29:795.e1e795.e7. 10.1016\/j.cmi.2023.01.027.","DOI":"10.1016\/j.cmi.2023.01.027"},{"key":"10.1016\/j.idnow.2025.105243_b0165","unstructured":"Nationales Antibiotika-Sensitivit\u00e4tstest-Komitee [Internet]. 2025. The EUCAST diffusion method. German NAC meeting for anaerobic bacteria. Anaerobic disk diffusion and beyond [cited January 9, 2025]. Available from: https\/\/\/www.nak-deutschland.org\/files\/nak-deutscland\/nak-2025\/anaerobic disk diffusion_German NAC_9 January 2025.pdf."},{"key":"10.1016\/j.idnow.2025.105243_b0170","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3343\/alm.2024.0159","article-title":"Evaluation of the disk Diffusion Test for Bacteroides fragilis Group Clinical Isolates","volume":"45","author":"Lee","year":"2025","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.idnow.2025.105243_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.anaerobe.2025.102969","article-title":"Comparison of disc diffusion and Sensititre\u00ae Broth Microdilution methods for antimicrobial susceptibility testing of Bacteroides fragilis group clinical isolates following the French guidelines","volume":"93","author":"Delvallez","year":"2025","journal-title":"Anaerobe"},{"key":"10.1016\/j.idnow.2025.105243_b0180","unstructured":"Delvallez G, Alauzat C, Diancourt L, Mazuet C, Barbut F, Marchandin H, et al., on behalf of the BFG AMR Collaborative Study group. Prevalence of species and antibiotic resistance within the Bacteroides fragilis group: national multicentre survey in France, 2022 \u2013 2023 Microbes 2024 congress, Lille, France, poster MC-P16."},{"key":"10.1016\/j.idnow.2025.105243_b0185","doi-asserted-by":"crossref","first-page":"e3842","DOI":"10.1093\/cid\/ciaa1479","article-title":"Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin\/tazobactam or meropenem from the MERINO study","volume":"73","author":"Henderson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idnow.2025.105243_b0190","unstructured":"CLSI M100 Performance Standards for Antimicrobial Susceptibility Testing 32nd ed. Wayne, PA. CLSI 2022, Clinical and Laboratory Standards Institute. https:\/\/ebookfinal.com\/download\/m100-performance-standards-for-antimicrobial-susceptibility-testing-32nd-edition-clsi-2022-clinical-and-laboratory-standards-institute\/."},{"key":"10.1016\/j.idnow.2025.105243_b0195","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1128\/jb.153.1.232-240.1983","article-title":"Porin channels in Escherichia coli: studies with b-lactams in intact cells","volume":"153","author":"Nikaido","year":"1983","journal-title":"J Bacteriol"},{"key":"10.1016\/j.idnow.2025.105243_b0200","doi-asserted-by":"crossref","DOI":"10.1006\/anae.2001.0385","article-title":"Description of complex forms of a porin in Bacteroides fragilis and possible implication of this protein in antibiotic resistance","volume":"7","author":"Odou","year":"2001","journal-title":"Anaerobe"},{"key":"10.1016\/j.idnow.2025.105243_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.anaerobe.2020.102207","article-title":"Epidemiology and microbiological features of anaerobic bacteremia in two French University hospitals","volume":"64","author":"Dumont","year":"2020","journal-title":"Anaerobe"},{"issue":"2","key":"10.1016\/j.idnow.2025.105243_b0210","first-page":"117","article-title":"Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019anesth\u00e9sie et de r\u00e9animation. guidelines for management of intra-abdominal infections","volume":"34","author":"Montravers","year":"2015","journal-title":"Anaesth Critic Care Pain Med"},{"key":"10.1016\/j.idnow.2025.105243_b0215","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.anaerobe.2019.01.011","article-title":"High prevalence of division II (cfiA positive) isolates among blood stream Bacteroides fragilis in Slovenia as determined by MALDI-TOF MS","volume":"58","author":"Jeverica","year":"2019","journal-title":"Anaerobe"},{"key":"10.1016\/j.idnow.2025.105243_b0220","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jac\/dkw436","article-title":"Phenotypic detection of the cfiA metallo-\u03b2-lactamase in Bacteroides fragilis with the meropenem-EDTA double-ended E-test and the ROSCO KPC\/MBL confirm kit","volume":"72","author":"Schwensen","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2025.105243_b0225","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1099\/jmm.0.031336-0","article-title":"Differentiation of division I (cfiA-negative) and division II (cfiA-positive) Bacteroides fragilis strains by matrix-assisted laser desorption \/ionization time-of-flight mass spectrometry","volume":"60","author":"Nagy","year":"2011","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.idnow.2025.105243_b0230","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.anaerobe.2018.04.004","article-title":"Bacteroides fragilis: a whole MALDI-based workflow from identification to confirmation of carbapenemase production for routine laboratories","volume":"54","author":"Cordovana","year":"2018","journal-title":"Anaerobe"},{"key":"10.1016\/j.idnow.2025.105243_b0235","unstructured":"EUCAST [Internet]. 2024. EUCAST guidance on When there are no breakpoints in breakpoint tables? Table 2. Antimicrobial agents relevant for the treatment of anaerobic bacteria with guidance for bacteria lacking breakpoints in standard EUCAST breakpoint tables. [cited September 9, 2024]. Available from: https:\/\/www.eucast.org\/bacteria\/clinical-breakpoints-and-interpretation\/when-there-are-no-breakpoints\/."},{"key":"10.1016\/j.idnow.2025.105243_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.anaerobe.2020.102245","article-title":"Antimicrobial susceptibility patterns of clinically significant Gram positive in in a Greek tertiary-care hospital 2017-2019","volume":"64","author":"Maraki","year":"2020","journal-title":"Anaerobe"},{"key":"10.1016\/j.idnow.2025.105243_b0245","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1128\/AAC.50.5.1887-1889.2006","article-title":"In vitro activities of DX -619 and four comparator agents against 376 anaerobic bacterial isolates","volume":"50","author":"Molitoris","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idnow.2025.105243_b0250","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1128\/AAC.00355-08","article-title":"Increasing trends in antimicrobial resistance among clinically important anaerobes and B. fragilis isolates causing nosocomial infections: emerging resistance to Carbapenems","volume":"52","author":"Liu","year":"2008","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.idnow.2025.105243_b0255","doi-asserted-by":"crossref","first-page":"e02206","DOI":"10.1128\/AAC.02206-17","article-title":"Evaluation of the in vitro activity of Eravacycline against a broad spectrum of recent clinical anaerobic isolates","volume":"62","author":"Snydman","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Infectious Diseases Now"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991925002222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991925002222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T21:28:43Z","timestamp":1782941323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666991925002222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2666991925002222"],"URL":"https:\/\/doi.org\/10.1016\/j.idnow.2025.105243","relation":{},"ISSN":["2666-9919"],"issn-type":[{"value":"2666-9919","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial susceptibility testing of anaerobes \u2212 Challenges and potential solutions for identifying breakpoints using the disk-diffusion method, based on re-analysis of a large panel of anaerobes","name":"articletitle","label":"Article Title"},{"value":"Infectious Diseases Now","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idnow.2025.105243","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105243"}}